Oruka Therapeutics’ (ORKA) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note published on Tuesday,Benzinga reports. Wedbush currently has a $165.00 target price on the stock.

Several other equities analysts also recently issued reports on ORKA. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Barclays increased their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Trading Up 0.7%

NASDAQ:ORKA opened at $108.12 on Tuesday. The company has a market cap of $7.16 billion, a PE ratio of -53.26 and a beta of -0.34. Oruka Therapeutics has a twelve month low of $14.08 and a twelve month high of $109.42. The company’s 50 day moving average is $86.50 and its two-hundred day moving average is $62.27.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts expect that Oruka Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares in the company, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 181,406 shares of company stock valued at $11,586,733. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Algert Global LLC lifted its holdings in Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares during the period. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the period. AlphaCentric Advisors LLC grew its stake in shares of Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after purchasing an additional 626 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.